|
Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors Clinical research trials and Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors. Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors clinical trial. Human subjects frequently get the finest healthcare available for their Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "F" Clinical Trials Conditions > Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors  Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
For Condition: Stage 4 Melanoma,Recurrent Melanoma,stage 4 prostate cancer,stage 4 breast cancer,recurrent breast cancer,unspecified adult solid tumor, protocol specific,recurrent prostate cancer
Status: No longer recruiting
Sponsor(s): Mayo Clinic Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of flavopiridol plus cisplatin or carboplatin in treating patients who have advanced solid tumors.
Details: OBJECTIVES: - Determine the maximum tolerated dose (MTD) of flavopiridol and cisplatin in patients with advanced solid tumors. (Part 1) - Determine the MTD of carboplatin when combined with flavopiridol in another group of patients with advanced solid tumors. (Part 2) - Determine the toxic effects of these regimens in this patient population. - Determine the objective clinical response in patients treated with this regimen. - Determine the pharmacokinetics of these regimens in this patient population. OUTLINE: This is a dose-escalation study of flavopiridol and cisplatin (part 1), followed by a dose-escalation study of carboplatin (part 2). - Patients receive flavopiridol IV over 24 hours. Two weeks later, patients receive cisplatin IV over 2 hours immediately followed by flavopiridol IV over 24 hours. Treatment with cisplatin/flavopiridol continues every 3 weeks in the absence of unacceptable toxicity or disease progression. Sequential dose escalation of flavopiridol is followed by sequential dose escalation of cisplatin. Cohorts of 3-6 patients receive escalating doses of flavopiridol and then cisplatin until the maximum tolerated dose (MTD) of the combination is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity. - Additional patients are accrued for part 2. Those patients receive carboplatin IV over 30 minutes immediately followed by flavopiridol IV over 24 hours. Treatment continues every 3 weeks in the absence of unacceptable toxicity or disease progression. Cohorts of 3-6 patients receive escalating doses of carboplatin until the MTD is determined. The MTD is defined as in part 1. PROJECTED ACCRUAL: Approximately 36-48 patients will be accrued for this study within 2 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed unresectable advanced solid tumor for which no standard therapy exists that is potentially curative or definitely capable of extending life expectancy - Biopsy confirmation of recurrent tumors required, unless sole site of disease is inaccessible bony and/or pulmonary metastases - Eligible solid tumors include, but not are limited to, prostate cancer, breast cancer, or melanoma - No lymphoma - No CNS metastases - Patients with primary brain tumors are eligible if they are not receiving antiepileptic medication(s) but are receiving stable doses of corticosteroids - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age: - 18 and over Sex: - Not specified Menopausal status: - Not specified Performance status: - ECOG 0-2 Life expectancy: - See Disease Characteristics - At least 12 weeks Hematopoietic: - WBC at least 3,500/mm^3 - Absolute neutrophil count at least 1,700/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 8 g/dL Hepatic: - Bilirubin within upper limit of normal (ULN) - AST and ALT no greater than 2.5 times ULN - Alkaline phosphatase no greater than 2.5 times ULN Renal: - Creatinine no greater than 1.5 times ULN Cardiovascular: - No New York Heart Association class III or IV heart disease - No history of angina Neurologic: - No grade 2 or greater peripheral neuropathy - No seizure disorder Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No uncontrolled infection PRIOR CONCURRENT THERAPY: Biologic therapy: - More than 4 weeks since prior immunotherapy - More than 4 weeks since prior biologic therapy - No concurrent immunotherapy Chemotherapy: - More than 4 weeks since prior chemotherapy (6 weeks for mitomycin and nitrosoureas) and recovered - No other concurrent chemotherapy Endocrine therapy: - See Disease Characteristics Radiotherapy: - More than 4 weeks since prior radiotherapy - No prior radiotherapy to more than 25% of bone marrow - No concurrent radiotherapy Surgery: - See Disease Characteristics
Total Enrollment:
Location and Contact Information:
Overall Study Official:
KeithBible, Study Chair, Mayo Clinic Cancer Center
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
United States
Additional Information:
Study ID Numbers: CDR0000066793; MAYO-950101,NCI-T97-0032
Study Start Date:
Record last reviewed: April 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003690
Other Stage 4 Melanoma Studies:
1. High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer
2. Herbal Therapy in Treating Women With Metastatic Breast Cancer
3. Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
4. Combination Chemotherapy and Peripheral Stem Cell Transplantation Followed by Interleukin-2 and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
5. T-Cell-Depleted Allogeneic Stem Cell Transplantation Followed By Donor Lymphocytes Given After Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Metastatic Breast Cancer
Related Studies:
Other Stage 4 Melanoma Clinical Trials
Other Minnesota Clinical Trials
Other Rochester Clinical Trials
Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
|
|
|
|
|
|
|
|
